Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Application entities : Abbvie inc. save search
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
Published: 2024-02-27 (Crawled : 01:00) - globenewswire.com
GNMSF | News | $284.55 3.83% 240
|
Health Technology
|
| O: -0.28%
H: 1.46%
C: 1.46%
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: 0.13%
H: 0.0%
C: 0.0%
GMAB | News | $28.97 0.94% 0.93% 450K
|
Health Technology
|
| O: -1.6%
H: 1.11%
C: 0.41%
epkinly fda license review application
AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application
Published: 2023-03-22 (Crawled : 13:00) - prnewswire.com
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: -0.7%
H: 0.77%
C: -1.29%
abbv-951 drug abbvie update application
AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age
Published: 2022-12-16 (Crawled : 13:00) - prnewswire.com
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: -0.64%
H: 0.78%
C: -0.97%
linzess fda drug children application
U.S. FDA Accepts for Priority Review the Biologics License Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma
Published: 2022-11-21 (Crawled : 14:00) - biospace.com/
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: 0.27%
H: 2.08%
C: 1.1%
cd20 duobody treatment fda application license review
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Published: 2022-07-18 (Crawled : 14:20) - globenewswire.com
GNMSF | News | $284.55 3.83% 240
|
Health Technology
|
| O: 0.15%
H: 4.93%
C: 2.47%
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: 0.0%
GMAB | News | $28.97 0.94% 0.93% 450K
|
Health Technology
|
| O: 0.82%
H: 1.15%
C: -1.16%
cd20 duobody treatment application authorization
AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine
Published: 2022-07-18 (Crawled : 07:00) - prnewswire.com
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: 0.0%
treatment ema application migraine authorization
AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expansion for the Preventive Treatment of Migraine
Published: 2022-06-21 (Crawled : 14:00) - biospace.com/
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: 1.48%
H: 0.0%
C: 0.0%
treatment fda expansion drug label application migraine
Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Eight Additional European Countries
Published: 2022-03-01 (Crawled : 10:00) - prnewswire.com
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
europe application authorization submission
AbbVie Submits Supplemental New Drug Application to U.S. FDA for cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder
Published: 2022-02-22 (Crawled : 14:30) - biospace.com/
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: -1.93%
H: 3.61%
C: 3.05%
vraylar new drug treatment fda order application drug major depressive disorder
Global Anesthetic Drugs Market (2021 to 2026) - by Drug Type, Route of Administration, Application and Geography
Published: 2022-02-18 (Crawled : 16:00) - prnewswire.com
AZNCF | News | $136.2 -4.19% 1.7K
|
Health Technology
|
| O: -0.64%
H: 0.0%
C: -2.99%
TEVA | $12.88 0.16% 0.0% 7.9M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -2.04%
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: -0.19%
H: 0.72%
C: -0.46%
ABT | News | $107.07 -0.2% 0.0% 4.9M
|
Health Technology
|
| O: -0.48%
H: 0.26%
C: -2.67%
AZN | News | $70.12 2.29% 2.24% 4.8M
|
Health Technology
|
| O: -1.02%
H: 0.43%
C: -0.84%
application drug
Outlook on the Inhalation Anesthesia Global Market to 2026 - by Product, Application, End-user and Region
Published: 2021-12-02 (Crawled : 18:00) - prnewswire.com
CTS | News | $43.77 0.78% 0.0% 110K
|
Electronic Technology
|
| O: 0.51%
H: 3.16%
C: 2.4%
BAX | $40.4 2.36% 0.0% 3.2M
|
Health Technology
|
| O: -0.25%
H: 2.3%
C: 1.79%
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
application
AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA)
Published: 2021-11-30 (Crawled : 13:30) - biospace.com/
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
ema europe application disease risankizumab
Global $191 Billion Orphan Drugs Markets to 2026: Therapeutic Applications in Rare and Orphan Diseases, Regulatory Framework, Patents, and Innovations
Published: 2021-08-05 (Crawled : 20:00) - prnewswire.com
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: -0.85%
H: 0.15%
C: -0.16%
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
AZN | News | $70.12 2.29% 2.24% 4.8M
|
Health Technology
|
| O: -2.02%
H: 0.09%
C: -1.38%
disease drug patent application rare
AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA
Published: 2021-04-07 (Crawled : 13:15) - prnewswire.com
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: 0.14%
H: 0.57%
C: -0.3%
fda risankizumab ema application
Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia
Published: 2021-02-25 (Crawled : 14:00) - biospace.com/
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: -0.19%
H: 0.76%
C: -1.06%
treatment drug new drug application presbyopia
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.